Biotech Stock Opportunity Overshadowed by Market Giants
While Eli Lilly (LLY) and Novo Nordisk (NVO) dominate investor attention in the weight-management sector, Viking Therapeutics (VKTX) emerges as a undervalued contender with a $3.7 billion market cap. The company's oral GLP-1/GIP candidate, VK2735, is poised for a Phase 2 data release in September 2025—a potential inflection point.
Previous trials showed promising results: the injectable formulation achieved up to 14.7% weight loss over 13 weeks, with 88% of participants exceeding 10% reduction. The upcoming oral data could disrupt the obesity treatment landscape currently led by Wegovy and Zepbound, particularly if it maintains efficacy with improved convenience.